Back to top
more

Celsion Corporation (CLSN)

(Delayed Data from NSDQ)

$2.18 USD

2.18
85,165

0.00 (-0.03%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.18 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

by Zacks Equity Research

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Implied Volatility Surging for Celsion (CLSN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

New Strong Sell Stocks for November 19th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Celsion Down on DMC Recommendation to Stop Liver Cancer Study

by Zacks Equity Research

Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.

Implied Volatility Surging for Celsion (CLSN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Sweta Killa headshot

Why Small-Cap ETFs & Stocks Outperformed Last Week

by Sweta Killa

Given the improvements in domestic economy, small-cap stocks led the way higher last week.

AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues

by Zacks Equity Research

AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.

Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

by Zacks Equity Research

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

by Zacks Equity Research

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

Ultragenyx Provides Preliminary Crysvita 2019 Revenues

by Zacks Equity Research

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

Applied Therapeutics Up on Positive Galactosemia Study Data

by Zacks Equity Research

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

by Zacks Equity Research

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

by Zacks Equity Research

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Celsion (CLSN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CLSN) Outperforming Other Medical Stocks This Year?

Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

    Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil

    by Zacks Equity Research

    Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.

    Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints

    by Zacks Equity Research

    Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.

    IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus

    by Zacks Equity Research

    IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    by Zacks Equity Research

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.